[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335457-105":59,"doc-detail-335457-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","safety-of-the-herbal-medicine-sh003-in-patients-with-solid-cancer-integrative-cancer-therapies-volume-23-110","Safety of the Herbal Medicine SH003 in Patients With Solid Cancer - Integrative Cancer Therapies Volume 23 - 1–10","","Background: SH003 is a novel herbal medicine containing Huang-Qi, Dang-Gui, and Gua-Lou-Gen, with reported anticancer activity rooted in traditional medicine. This phase I study addressed the need for safe and tolerable oncology treatments. Methods: Conducted at Ajou University Hospital and Gachon University Gil Medical Center, the single-arm, open-label dose-escalation trial evaluated safety and targeted determination of the maximum tolerated dose. Results: The maximum tolerated dose was 9600 mg/day, with most adverse events mild, including dizziness and nausea. Conclusions: SH003 demonstrates safety and tolerability up to 9600 mg/day, supporting further efficacy research.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/safety-of-the-herbal-medicine-sh003-in-patients-with-solid-cancer-integrative-cancer-therapies-volume-23-110/335457/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/safety-of-the-herbal-medicine-sh003-in-patients-with-solid-cancer-integrative-cancer-therapies-volume-23-110/335457.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is SH003 and why was this study conducted?","Question",{"text":112,"@type":113},"SH003 is a novel herbal medicine composed of Huang-Qi, Dang-Gui, and Gua-Lou-Gen. The study was conducted to explore safe and effective oncology treatment options and establish tolerability in patients with solid cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the dose escalation designed in the phase I trial?",{"text":117,"@type":113},"The trial used a single-arm, open-label, dose-escalation approach with a 3 + 3 design. SH003 doses were escalated from 4800 to 9600 mg per day.",{"name":119,"@type":110,"acceptedAnswer":120},"What was the maximum tolerated dose of SH003 and what adverse events were observed?",{"text":121,"@type":113},"The maximum tolerated dose was determined to be 9600 mg/day. Most adverse events were mild, with dizziness and nausea reported as primary examples.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335457,1790216484,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Safety of the Herbal Medicine SH003 in Patients With Solid Cancer: A Multi-Center, Single-Arm, Open-Label, Dose-Escalation Phase I Study  \nIntegrative Cancer Therapies Volume 23: 1–10  \n© The Author(s) 2024  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15347354241293451](DOI: 10.1177/15347354241293451)[ ](DOI: 10.1177/15347354241293451)[journals.sagepub.com/home/ict](journals.sagepub.com/home/ict)  \nChunhoo Cheon, KMD, PhD 1, Hyun Woo Lee, MD2, Sun Jin Sym, MD, PhD3, and Seong-Gyu Ko, KMD, PhD 1  \nAbstract  \nBackground: SH003, a novel herbal medicine comprising Huang-Qi, Dang-Gui, and Gua-Lou-Gen, has historical roots in traditional medicine with reported anticancer properties. The need to explore safe and effective treatments in oncology underlines the importance of this study. Methods: This phase I trial, conducted at Ajou University Hospital and Gachon University Gil Medical Center in Korea, adopted a single-arm, open-label, dose-escalation design. It aimed to evaluate the safety of escalated doses of SH003 in patients with various solid cancers, focusing on determining its maximum tolerated dose. Participants with confirmed solid cancers, unresponsive to standard treatments, were enrolled. The dosage of SH003 was escalated from 4800 to 9600 mg per day, using a 3 + 3 design. Safety was assessed based on the Common Terminology Criteria for Adverse Events ver. 5.0. Results: The study established that the maximum tolerated dose of SH003 is 9600 mg/day. Most adverse events were mild, primarily including dizziness and nausea, indicating the tolerability of SH003 at this dosage. Conclusions: SH003 demonstrates safety and promises as an anticancer treatment at doses up to 9600 mg/day. This research supports further investigation into its efficacy for cancer therapy, emphasizing the significance of natural products in oncology, particularly concerning patient safety and tolerance.  \nKeywords  \nherbal medicine, cancer, safety, phase I trial, maximum tolerated dose, natural product, SH003 Submitted February 21, 2024; revised August 1, 2024; accepted October 8, 2024  \nIntroduction  \nCancer, a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, is a leading cause of death globally, accounting for nearly 10 million deaths in 2020.1 By 2040, the global cancer burden is projected to reach 28.4 million cases, marking a 47% increase from 2020.2 Despite extensive efforts and substantial resources devoted to cancer research and treatment, cancer continues to be a pressing health issue worldwide. As the cancer treatment market expands due to rising global prevalence and medical advancements, a corresponding increase in interest toward natural products has emerged.3 These products, rich in bioactive compounds, are increasingly explored not only as potential sources of novel anticancer agents but also for their roles in alleviating symptoms associated with cancer and its treatment.4, 5 Despite significant advancements in cancer therapies, the overall rate remains  \nhigh, underscoring the necessity for innovative approaches.6 Herbal medicine and natural products are increasingly explored for their potential to offer new therapeutic options in cancer treatment.7,8  \n1 Kyung Hee University, Dongdaemun-gu, Seoul, Republic of Korea 2Ajou University Hospital, Suwon-si, Gyeonggi-do, Republic of Korea 3Gachon University Gil Medical Center, Namdong-gu, Incheon, Republic of Korea  \nCorresponding Authors:  \nSun Jin Sym, Department of Medical Oncology, Gachon University Gil Medical Center, 21, Namdong-Daero 774 Beon-Gil, Namdong-Gu, Incheon 21565, Republic of Korea.  \nEmail: [esympson@gmail.com](esympson@gmail.com)  \nSeong-Gyu Ko, Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-Ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.  \nEmail: [epiko@khu.ac.kr](epiko@khu.ac.kr)","cbCairzyQbHBZrXx","https://ap.wps.com/l/cbCairzyQbHBZrXx","pdf",589007,"English","# Abstract\n# Keywords\n# Introduction\n# Corresponding Authors","[{\"question\":\"What is SH003 and why was this study conducted?\",\"answer\":\"SH003 is a novel herbal medicine composed of Huang-Qi, Dang-Gui, and Gua-Lou-Gen. The study was conducted to explore safe and effective oncology treatment options and establish tolerability in patients with solid cancers.\"},{\"question\":\"How was the dose escalation designed in the phase I trial?\",\"answer\":\"The trial used a single-arm, open-label, dose-escalation approach with a 3 + 3 design. SH003 doses were escalated from 4800 to 9600 mg per day.\"},{\"question\":\"What was the maximum tolerated dose of SH003 and what adverse events were observed?\",\"answer\":\"The maximum tolerated dose was determined to be 9600 mg/day. Most adverse events were mild, with dizziness and nausea reported as primary examples.\"}]","Safety of the Herbal Medicine SH003 in Patients With Solid Cancer - Integrative Cancer Therapies Volume 23 - 1–10 | PDF",1790011048,25]